Events in AML-HR trial by G-CSF versus not randomization
. | Comparison, % . | . | . | . | |
|---|---|---|---|---|---|
. | G-CSF . | No G-CSF . | OR/HR (95% CI) . | P . | |
| Reasons for failure | |||||
| Induction death | 8 | 9 | — | — | |
| Resistant disease | 34 | 30 | — | — | |
| CR rate | 58 | 61 | 1.12 (0.72-1.74) | .7 | |
| Outcome after CR* | |||||
| Death in CR | 27 | 19 | — | .9 | |
| Relapse rate | 58 | 66 | — | .4 | |
| Disease-free survival* | 31 | 28 | 0.89 (0.65-1.22) | .5 | |
| Overall survival* | 22 | 22 | 1.03 (0.81-1.31) | .8 | |
. | Comparison, % . | . | . | . | |
|---|---|---|---|---|---|
. | G-CSF . | No G-CSF . | OR/HR (95% CI) . | P . | |
| Reasons for failure | |||||
| Induction death | 8 | 9 | — | — | |
| Resistant disease | 34 | 30 | — | — | |
| CR rate | 58 | 61 | 1.12 (0.72-1.74) | .7 | |
| Outcome after CR* | |||||
| Death in CR | 27 | 19 | — | .9 | |
| Relapse rate | 58 | 66 | — | .4 | |
| Disease-free survival* | 31 | 28 | 0.89 (0.65-1.22) | .5 | |
| Overall survival* | 22 | 22 | 1.03 (0.81-1.31) | .8 | |
For G-CSF, the number of patients randomly assigned to the group was 178; for no G-CSF, n = 178.
— indicates not calculated.
Outcome at 4 years is given.